Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

ArQule Bringing In $31M For Cancer Drug Development

Jan. 26, 2005

By Jennifer Boggs

GTC Is Raising $10M, Aiming For Transgenic Drug Approval

Jan. 25, 2005

By Jennifer Boggs

GTC Is Raising $10M, Aiming For Transgenic Drug Approval

Jan. 25, 2005

By Jennifer Boggs

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

Jan. 24, 2005

By Jennifer Boggs

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

Jan. 24, 2005

By Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Compound Therapeutics Gets $15.5M In Expanded Financing

Jan. 19, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...